Rating the Nation’s Best and Worst Jobs
According to this year’s edition of “Jobs Rated Almanac” the nation’s single best job in terms of low stress, high compensation, lots of autonomy, tremendous hiring demand and several other key criteria, is biologist.
Battling Hunger With Biotechnology
Biotech Can Be Useful Development Tool, Scientists Say
Motorola shedding biochip biz
Motorola Inc. has put its life sciences business up for sale in a move that is dashing CEO Christopher Galvin’s dream of making biochips the company’s next big success.
Drug makers need a cure for the manufacturing crunch
Over the next several years, growth in demand for biotech production is estimated to outstrip the growth in supply.
Celera Shifts Marketing of Database
The main job of marketing and distributing the database will be shifted to Celera’s sister company, the Applied Biosystems Group, which makes equipment used to study genes and proteins
Was the U.S. government cheated on DNA decoder?
The scribblings of Henry Huang helped start the great race to map the human genome, and they may help settle allegations that the U.S. government got robbed on the way to the finish.
Cultivating Prosperous Partnerships
Like dedicated gardeners — who know that it’s not enough to merely plant seeds and bulbs to create a flourishing landscape — pharmaceutical companies have come to realize that tending to their partnering relationships is critical to achieving the best results.
Harvesting the Fruits of Plant Genomics
Pioneer Hi-Bred President Richard McConnell explains how geneticists are revolutionizing crops, yields — even the humble corn chip
Pa. uses tobacco settlement to fund biotech
Its efforts reflect a larger trend of states targeting bioscience as a source of future jobs and revenue. Overall, at least 41 states have instituted initiatives in recent years to attract new life-sciences companies, according to research conducted by Columbus, Ohio-based nonprofit organization Battelle Memorial Institute
Biotech stocks show indication of rebounding
Biotechnology stocks, down sharply since late last year because of a raft of bad news, appeared to begin a comeback last week as clinical trials results were leaked in advance of a major scientific meeting.